SV Health Investors’ Dementia Discovery Fund Announces $269m Final Close of DDF-2

Packaging Compliance Labs Completes Acquisition of Quest Engineering Solutions, Expands Testing Capabilities and East Coast Presence

SUN Behavioral Health Acquires Seaside’s Community Agencies, Expanding Access to Community-Based Mental Health Services Across the Southeast

Centauri Health Solutions Acquires MedAllies, Broadens Health Data Network to Support Mission Critical Use Cases
British Patient Capital announces £25m commitment to SV Health Investors’ Dementia Discovery Fund 2

Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment

2024 SV Therapeutics Impact & ESG Report
Read More

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas

Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System

SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise

Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure

Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More

SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion

Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics

SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner

Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership

Merck to Acquire Caraway Therapeutics, Inc.

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 20 May 2025SV NewsSV Health Investors’ Dementia Discovery Fund Announces $269m Final Close of DDF-2
- 19 May 2025Portfolio NewsAlchemab Therapeutics on BiotechTV
- 15 May 2025Portfolio NewsQuiver Bioscience and QurAlis Announce Research Collaboration to Advance Novel Therapeutic Approach for Fragile X Syndrome
- 15 May 2025Portfolio NewsQurAlis Announces Exclusive License on Novel Mechanism for Fragile X Syndrome (FXS) to Enable Development of First Potential Disease-Modifying Therapy
- 15 May 2025Portfolio NewsAviadoBio Announces ASPIRE-FTD Phase 1/2 Clinical Trial in the UK at Cambridge University Hospitals NHS Foundation Trust, Cardiff and Vale University Health Board, and University College London
- 14 May 2025Portfolio NewsTherini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline
- 6 May 2025Portfolio NewsAlchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company
- 1 May 2025Portfolio NewsAviadoBio Announces Completion of Second Cohort in Phase 1/2 ASPIRE-FTD Clinical Trial Studying AVB-101 for FTD-GRN
- 31 March 2025Portfolio NewsEndlyz Therapeutics launches and unveils its portfolio of programmes targeting Parkinson’s disease
- 20 March 2025Portfolio NewsNitrase Therapeutics Unveils Protein with Newly Characterized Enzymatic Function Involved in the Pathogenesis of Parkinson’s Disease
- 20 March 2025SV NewsBritish Patient Capital announces £25m commitment to SV Health Investors’ Dementia Discovery Fund 2
- 13 March 2025Portfolio NewsMontara Therapeutics Closes $20M Oversubscribed Seed Expansion, Appoints Troy Wilson as Chairman of the Board